ProCE Banner Activity

Phase III IDHENTIFY Trial of Enasidenib vs Conventional Care in Late-Stage IDH2-Mutated R/R AML: Analysis by IDH2 Mutation

Slideset Download
Comutational profiles and survival benefits from enasidenib appear to differ based on presence of the IDH2 R140 or IDH2 R172 mutation, warranting additional research to clarify the influence of the various mutations on treatment outcomes.

Released: June 13, 2022

Expiration: June 12, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab